董事长被刑拘，北大医药易主后风波不断

Core Viewpoint - The recent criminal detention of Xu Xiren, the chairman and president of Peking University Pharmaceutical Co., Ltd., raises concerns about the company's future, especially after losing its largest client, Peking University International Hospital, and facing operational challenges [1][2]. Group 1: Company Leadership and Control - Xu Xiren has been temporarily unable to perform his duties due to personal reasons and is currently under investigation, with Chen Yuezhong and Yu Mengchuan taking over his responsibilities [2][3]. - Xu Xiren became the actual controller of Peking University Pharmaceutical in June 2024, following a series of ownership changes that severed ties with Peking University [3][4]. - The company has undergone significant management changes since Xu's appointment, with multiple resignations from key positions [3]. Group 2: Business Operations and Financial Impact - The company is undergoing a "de-Peking University" process, which includes changing its name and severing ties with its historical roots [4][5]. - Peking University International Hospital was the company's largest client, contributing over 30% of sales annually, with significant revenue from related transactions [6]. - The termination of the contract with the hospital is expected to lead to a revenue decline of approximately 600 million yuan (about 29.13% of the latest audited revenue) and a net profit decrease of around 40 million yuan (about 28.99% of the latest audited net profit) starting from June 2025 [7]. - For the first nine months of 2025, the company reported a revenue of 1.23 billion yuan, a year-on-year decrease of 19.8%, with a significant drop in third-quarter revenue by 48% [7].